News for PsyBio Therapeutics Corp. (PSYBF)

PsyBio Therapeutics (PSYB:CA) (PSYBF) has been given the go-ahead to produce biosynthetic tryptamines after waiting for authorization for over two years, the company said Friday.PsyBio...

Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances via local measures.

Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental health conditions and how clinical dat

Oxford, Ohio and Denver, Colorado - April 6, 2023 (Newsfile Corp.) (Investorideas.com Newswire) PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" ...

Biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed four new U.S. Patent Cooperation Treaty (PCT) applications aiming to convert five provisional patent applications.

Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and further guidance for pre-clinical research and studies with young participants.

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) reported its unaudited interim financial results for the three and nine-month period ended September 30, 2022.

The current clinical scenario sets psilocybin as one of the most advanced psychedelics, expected to become legally approved in the US sometime between the 2023-2024 period and to become available as of Januar

The Chart represents the liquidity positions of the 21 Psychedelic sector companies in the Viridian Value Tracker database.

PsyBio Therapeutics (TSXV: PSYB) (OTCQB: PSYBF), a biotech developing medicines based on naturally-occurring psychedelic substances, and mushroom producer Red Light Holland Corp. (OTC Pink: TRUFF) announced the

Vancouver, Kelowna, Delta, BC - May 13, 2022 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its w...

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Vancouver drug-research companies are seeking cheaper ways to produce psychedelic mushrooms, or the active ingredient psilocybin, to cater to new demand.

Burns & Levinson Expands National Cannabis Business Law Practice  Boston-based Burns & Levinson LLP annou...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...